|
Variable
|
Footwear intervention group (n = 47)
|
Control group (n = 47)
|
|---|
|
Sex, male, n (%)
|
40 (85%)
|
43 (91%)
|
|
Age, years
|
62.6 (17.0)
|
62.4 (13.7)
|
|
BMI, kg/m2
|
30.2 (6.4)
|
32.0 (7.0)
|
|
Ethnicity, n (%)
|
|
NZ European
|
28 (62%)
|
26 (57%)
|
|
Pacific
|
6 (13%)
|
11 (23%)
|
|
Asian
|
7 (16%)
|
5 (11%)
|
|
Māori
|
4 (9%)
|
4 (9%)
|
|
Gout history, mean (SD)
|
|
Disease duration (years)
|
12.2 (11.2)
|
13.6 (12.3)
|
|
Flares prior 3 months
|
0.7 (0.9)
|
0.4 (0.7)
|
|
Foot tophus, n (%)
|
9 (19%)
|
17 (36%)
|
|
Any tophus, n (%)
|
13 (28%)
|
24 (51%)
|
|
Serum urate, mmol/L
|
0.39 (0.13)
|
0.38 (0.11)
|
|
Medications, n (%)
|
|
Urate-lowering therapy
|
33 (72%)
|
30 (64%)
|
|
Colchicine
|
15 (33%)
|
17 (36%)
|
|
Prednisone
|
9 (20%)
|
10 (21%)
|
|
NSAID
|
12 (27%)
|
13 (29%)
|
|
Diuretic
|
8 (18%)
|
5 (11%)
|
|
Medical History, n (%)
|
|
Hypertension
|
22 (48%)
|
22 (54%)
|
|
Cardiovascular disease
|
13 (28%)
|
11 (24%)
|
|
Type 2 diabetes
|
7 (15%)
|
3 (7%)
|
|
Peripheral vascular disease
|
4 (9%)
|
3 (7%)
|
|
Peripheral neuropathy
|
3 (7%)
|
5 (11%)
|
- BMI body mass index, NSAID non-steroidal anti-inflammatory drug
